According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
A number of other equities analysts have also recently weighed in on the stock. Robert W. Baird reaffirmed an outperform rating and set a $7.00 price objective on shares of Curis in a research report on Wednesday, September 7th. FBR & Co reaffirmed a buy rating on shares of Curis in a research report on Thursday, September 8th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $4.56.
Shares of Curis (NASDAQ:CRIS) opened at 2.36 on Monday. The stock has a 50 day moving average price of $1.82 and a 200 day moving average price of $1.74. Curis has a one year low of $1.25 and a one year high of $3.18. The company’s market capitalization is $305.55 million.
Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.09) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.09). The firm earned $1.70 million during the quarter, compared to analysts’ expectations of $2.05 million. Curis had a negative net margin of 526.72% and a negative return on equity of 65.51%. The firm’s quarterly revenue was down 19.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.06) EPS. On average, equities research analysts predict that Curis will post ($0.38) earnings per share for the current year.
In related news, major shareholder Discovery Technologie Aurigene purchased 10,208,333 shares of the business’s stock in a transaction that occurred on Wednesday, September 7th. The shares were purchased at an average cost of $2.40 per share, for a total transaction of $24,499,999.20. Following the purchase, the insider now directly owns 27,328,464 shares of the company’s stock, valued at $65,588,313.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 6.09% of the company’s stock.
A number of large investors have recently made changes to their positions in CRIS. Royal Bank of Canada raised its stake in shares of Curis by 4.0% in the first quarter. Royal Bank of Canada now owns 803,909 shares of the company’s stock valued at $1,294,000 after buying an additional 30,894 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Curis by 2.5% in the first quarter. Geode Capital Management LLC now owns 772,054 shares of the company’s stock valued at $1,243,000 after buying an additional 18,476 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of Curis by 1.3% in the first quarter. BlackRock Fund Advisors now owns 4,555,408 shares of the company’s stock valued at $7,334,000 after buying an additional 57,624 shares in the last quarter. State Street Corp raised its stake in shares of Curis by 5.4% in the first quarter. State Street Corp now owns 1,452,409 shares of the company’s stock valued at $2,341,000 after buying an additional 73,759 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in shares of Curis during the second quarter valued at approximately $359,000. Hedge funds and other institutional investors own 52.36% of the company’s stock.
Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.